Benutzerspezifische Werkzeuge

Information zum Seitenaufbau und Sprungmarken fuer Screenreader-Benutzer: Ganz oben links auf jeder Seite befindet sich das Logo der JLU, verlinkt mit der Startseite. Neben dem Logo kann sich rechts daneben das Bannerbild anschließen. Rechts daneben kann sich ein weiteres Bild/Schriftzug befinden. Es folgt die Suche. Unterhalb dieser oberen Leiste schliesst sich die Hauptnavigation an. Unterhalb der Hauptnavigation befindet sich der Inhaltsbereich. Die Feinnavigation findet sich - sofern vorhanden - in der linken Spalte. In der rechten Spalte finden Sie ueblicherweise Kontaktdaten. Als Abschluss der Seite findet sich die Brotkrumennavigation und im Fussbereich Links zu Barrierefreiheit, Impressum, Hilfe und das Login fuer Redakteure. Barrierefreiheit JLU - Logo, Link zur Startseite der JLU-Gießen Direkt zur Navigation vertikale linke Navigationsleiste vor Sie sind hier Direkt zum Inhalt vor rechter Kolumne mit zusaetzlichen Informationen vor Suche vor Fußbereich mit Impressum

Artikelaktionen

Publikationen

 

Ausgewählte Publikationen

Helmrich N, Roderfeld M, Baier A, Windhorst A, Herebian D, Mayatepek E, Dierkes C, Ocker M, Glebe D, Christ B, Churin Y, Irungbam K, Roeb E. Pharmacological Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4 Mice. Cell Mol Gastroenterol Hepatol. 2021 Dec 23:S2352-345X(21)00263-0. doi: 10.1016/j.jcmgh.2021.12.013. Epub ahead of print. PMID: 34954190.

Kostyusheva A, Brezgin S, Glebe D, Kostyushev D, Chulanov V. Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification. Emerg Microbes Infect. 2021 Dec;10(1):2264-2275. doi: 10.1080/22221751.2021.2006580. PMID: 34767497; PMCID: PMC8648018.

Pflüger LS, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann JH, Pfefferle S, Dandri M, Schulze Zur Wiesch J, Lütgehetmann M. Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Rep. 2021 Aug 28;3(6):100356. doi: 10.1016/j.jhepr.2021.100356. PMID: 34712932; PMCID: PMC8531665.

Jo WK, Alfonso-Toledo JA, Salas-Rojas M, Almazan-Marin C, Galvez-Romero G, García-Baltazar A, Obregón-Morales C, Rendón-Franco E, Kühne A, Carvalho-Urbieta V, Rasche A, Brünink S, Glebe D, Aguilar-Setién Á, Drexler JF. Natural co-infection of divergent hepatitis B and C virus homologues in carnivores. Transbound Emerg Dis. 2021 Oct 4. doi: 10.1111/tbed.14340. Epub ahead of print.
PMID: 34606685.

Kirstgen M, Müller SF, Lowjaga KAAT, Goldmann N, Lehmann F, Alakurtti S, Yli-Kauhaluoma J, Baringhaus KH, Krieg R, Glebe D, Geyer J. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening. Viruses. 2021 Jul 29;13(8):1489. doi: 10.3390/v13081489. PMID: 34452354; PMCID: PMC8402622.

Safadi R, Khoury T, Saed N, Hakim M, Jamalia J, Nijim Y, Farah N, Nuser T, Natur N, Mahamid M, Amer J, Roppert PL, Gerlich WH, Glebe D. Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac. Vaccines (Basel). 2021 Apr 1;9(4):331. doi: 10.3390/vaccines9040331. PMID: 33915943; PMCID:
PMC8066861.

Kirstgen M, Lowjaga KAAT, Müller SF, Goldmann N, Lehmann F, Glebe D, Baringhaus KH, Geyer J. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors. Viruses. 2021 Apr 12;13(4):666. doi: 10.3390/v13040666. PMID: 33921515; PMCID: PMC8068820.

Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-
Register-Nr. 021-11). Z Gastroenterol. 2021 Jul;59(7):691-776. German. doi:10.1055/a-1498-2512. Epub 2021 Jul 12. PMID: 34255317.

Brezgin S, Kostyusheva A, Bayurova E, Volchkova E, Gegechkori V, Gordeychuk I, Glebe D, Kostyushev D, Chulanov V. Immunity and Viral Infections: Modulating Antiviral Response via CRISPR-Cas Systems. Viruses. 2021 Jul 15;13(7):1373. doi:10.3390/v13071373. PMID: 34372578; PMCID: PMC8310348.

Palatini M, Müller SF, Lowjaga KAAT, Noppes S, Alber J, Lehmann F, Goldmann N, Glebe D, Geyer J. Mutational Analysis of the GXXXG/A Motifs in the Human Na<sup>+</sup>/Taurocholate Co-Transporting Polypeptide NTCP on Its Bile Acid Transport Function and Hepatitis B/D Virus Receptor Function. Front Mol Biosci. 2021 Jun 22;8:699443. doi: 10.3389/fmolb.2021.699443. PMID: 34239896; PMCID:PMC8257933.

Kostyusheva A, Brezgin S, Babin Y, Vasilyeva I, Glebe D, Kostyushev D, Chulanov V. CRISPR-Cas systems for diagnosing infectious diseases. Methods. 2021 Apr 9:S1046-2023(21)00099-2. doi: 10.1016/j.ymeth.2021.04.007. Epub ahead of print. PMID: 33839288; PMCID: PMC8032595.

Churin Y, Irungbam K, Imiela CS, Schwarz D, Mollenkopf HJ, Drebber U, Odenthal M, Pak O, Huber M, Glebe D, Roderfeld M, Roeb E. Lipid Storage and Interferon Response Determine the Phenotype of Ground Glass Hepatocytes in Mice and Humans. Cell Mol Gastroenterol Hepatol. 2021;12(2):383-394. doi: 10.1016/j.jcmgh.2021.03.009. Epub 2021 Mar 23. PMID: 33766783; PMCID:PMC8255940.

Rasche A, Lehmann F, Goldmann N, Nagel M, Moreira-Soto A, Nobach D, de Oliveira Carneiro I, Osterrieder N, Greenwood AD, Steinmann E, Lukashev AN, Schuler G, Glebe D, Drexler JF; Equid HBV Consortium. A hepatitis B virus causes chronic infections in equids worldwide. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2013982118. doi: 10.1073/pnas.2013982118. PMID: 33723007; PMCID:PMC8020657.

Zimmermann R, Külper-Schiek W, Steffen G, Gillesberg Lassen S, Bremer V, Dudareva S; die Hepatitis-Monitoring-Arbeitsgruppe. Wie lässt sich die Eliminierung von Hepatitis B, C und D in Deutschland messen? Ergebnisse eines interdisziplinären Arbeitstreffens [How to assess the elimination of viral
hepatitis B, C, and D in Germany? Outcomes of an interdisciplinary workshop]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Jan;64(1):77-90. German. doi: 10.1007/s00103-020-03260-2. Epub 2020 Dec 16. PMID: 33326051; PMCID: PMC7772161.

Lowjaga KAAT, Kirstgen M, Müller SF, Goldmann N, Lehmann F, Glebe D, Geyer J. Long-term inhibition of the hepatitis B and D virus receptor NTCP by taurolithocholic acid. Am J Physiol Gastrointest Liver Physiol. 2021 Jan 1;320(1):G66-G80. doi: 10.1152/ajpgi.00263.2020. Epub 2020 Nov 11. PMID:33174454.

Glebe D, Goldmann N, Lauber C, Seitz S. HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. Antiviral Res. 2021 Feb;186:104973. doi: 10.1016/j.antiviral.2020.104973. Epub 2020 Nov 6. PMID: 33166575.

Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D,Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol. 2021 Feb;74(2):283-292. doi:
10.1016/j.jhep.2020.08.039. Epub 2020 Sep 12. PMID: 32931877.

Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent Proechimys semispinosus. Paraskevopoulou S, Pirzer F, Goldmann N, Schmid J, Corman VM, Gottula LT, Schroeder S, Rasche A, Muth D, Drexler JF, Heni AC, Eibner GJ, Page RA, Jones TC, Müller MA, Sommer S*, Glebe D*, Drosten C*. 2020Proc. Natl. Acad. Sci. U. S. A. 117:17977-17983. (*shared senior authors)

Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids. Kirstgen M, Lowjaga KAAT, Müller SF, Goldmann N, Lehmann F, Alakurtti S, Yli-Kauhaluoma J, Glebe D, Geyer J. 2020. Sci Rep. 10(1):21772.

HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals. Glebe D, Goldmann N, Lauber C, Seitz S. 2020.  Antiviral Res. 186:104973. doi: 10.1016/j.antiviral.2020.104973. Online ahead of print. (Review)

Enigmatic PreS deletions in hepatitis B virus DNA. Gerlich WH, Glebe D. 2020. Virus Genes. 56(6):675-676. (Editorial)

Cholestasis impairs hepatic lipid storage via AMPK and CREB signaling in hepatitis B virus surface protein transgenic mice. Cornberg M, Glebe D. 2020. Editorial: which factors influence HBsAg levels in HBV-infected patients? Aliment Pharmacol Ther. 52(3):547-548. (Editorial). Irungbam K, Roderfeld M, Glimm H, Hempel F, Schneider F, Hehr L, Glebe D, Churin Y, Morlock G, Yüce I, Roeb E. 2020. Lab Invest. 100(11):1411-1424.

ICTV Virus Taxonomy Profile: Hepadnaviridae. Magnius L, Mason WS, Taylor J, Kann M, Glebe D, Dény P, Sureau C, Norder H. ICTV Report Consortium. 2020. J Gen Virol. 2020. 101(6):571-572.

Guideline for testing chemical disinfectants regarding their virucidal activity within the field of human medicine : as of December 1st, 2014 Prepared by the German Association for the Control of Virus Diseases (DVV) and the Robert Koch Institute (RKI). Rabenau HF, Schwebke I, Blümel J, Eggers M, Glebe D, Rapp I, Sauerbrei A, Steinmann E, Steinmann J, Willkommen H, Wutzler P. 2020. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 63(5):645-655.

Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: a potential source of misunderstandings. Gerlich WH, Glebe D, Kramvis A, Magnius LO. 2020Virus Genes. 56(2):109-119.

Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige : Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V. Glebe D, van Bömmel F, Dudareva S, Gärtner B, Monazahian M, Roß S, Rösler J, Slanina H, Spickhoff A, Thanheiser M, Schüttler CG. 2020Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 63(2):218-225.

Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Rinker F, Bremer CM, Schröder K, Wiegand SB, Bremer B, Manns MP, Kraft AR, Wedemeyer H, Yang L, Pavlovic V, Wat C, Gerlich WH, Glebe D, Cornberg M. 2020Liver Int. 40(2):324-332.

Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2. Irungbam K, Churin Y, Matono T, Weglage J, Ocker M, Glebe D, Hardt M, Koeppel A, Roderfeld M, Roeb E. 2020. Lab Invest. 100(3):454-465.

Highly diversified shrew hepatitis B viruses corroborate ancient origins and divergent infection patterns of mammalian hepadnaviruses. Rasche A, Lehmann F, König A, Goldmann N, Corman VM, Moreira-Soto A, Geipel A, van Riel D, Vakulenko YA, Sander AL, Niekamp H, Kepper R, Schlegel M, Akoua-Koffi C, Souza BFCD, Sahr F, Olayemi A, Schulze V, Petraityte-Burneikiene R, Kazaks A, Lowjaga KAAT, Geyer J, Kuiken T, Drosten C, Lukashev AN, Fichet-Calvet E, Ulrich RG, Glebe D*, Drexler JF*. 2019 Proc Natl Acad Sci U S A. 116:17007-17012. (*shared senior authors).

Replenishment of Hepatitis B Virus cccDNA Pool Is Restricted by Baseline Expression of Host Restriction Factors In Vitro. Brezgin S, Kostyusheva A, Bayurova E, Gordeychuk I, Isaguliants M, Goptar I, Nikiforova A, Smirnov V, Volchkova E, Glebe D, Kostyushev D, Chulanov V. 2019. Microorganisms. 7(11):533.

Why all blood donations should be tested for hepatitis E virus (HEV). Denner J, Pischke S, Steinmann E, Blümel J, Glebe D. 2019. . BMC Infect Dis. 19(1):541. (Review)

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection. Faculty Members*. 2019. J Hepatol. 71(2):397-408. (*D. Glebe was one of the Faculty Member).

A global scientific strategy to cure hepatitis B. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups*; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F. 2019Lancet Gastroenterol Hepatol. 4(7):545-558. (*D. Glebe was Member of the ICE-HBV Working Groups).

Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling. Gerresheim GK, Bathke J, Michel AM, Andreev DE, Shalamova LA, Rossbach O, Hu P, Glebe D, Fricke M, Marz M, Goesmann A, Kiniry SJ, Baranov PV, Shatsky IN, Niepmann M. 2019. Int J Mol Sci. 15;20(6):1321.

Host Biology and Anthropogenic Factors Affect Hepadnavirus Infection in a Neotropical Bat. Hiller T, Rasche A, Brändel SD, König A, Jeworowski L, Teague O'Mara M, Cottontail V, Page RA, Glebe D, Drexler JF, Tschapka M. 2019. Ecohealth. 16(1):82-94.

Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F.  Gut. 2018 Nov;67(11):2045-2053

A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.de Carvalho Dominguez Souza BF, König A, Rasche A, de Oliveira Carneiro I, Stephan N, Max Corman V, Luise Roppert P, Goldmann N, Kepper R, Franz Müller S, Völker C, Junior Souza de Souza A, Soares Gomes-Gouvêa M, Moreira-Soto A, Stöcker A, Nassal M, Roberto Franke C, Renato Rebello Pinho J, do Carmo Pereira Soares M, Geyer J, Lemey P, Drosten C, Martins Netto E, Glebe D*, Felix Drexler J*. J Hepatol. 2018 Jun;68(6):1114-1122., (*shared senior authors).

Ancient hepatitis B viruses from the Bronze Age to the Medieval period. Mühlemann B, Jones TC, Damgaard PB, Allentoft ME, Shevnina I, Logvin A, Usmanova E, Panyushkina IP, Boldgiv B, Bazartseren T, Tashbaeva K, Merz V, Lau N, Smrčka V, Voyakin D, Kitov E, Epimakhov A, Pokutta D, Vicze M, Price TD, Moiseyev V, Hansen AJ, Orlando L, Rasmussen S, Sikora M, Vinner L, Osterhaus ADME, Smith DJ, Glebe D, Fouchier RAM, Drosten C, Sjögren KG, Kristiansen K, Willerslev E. Nature. 2018 May;557(7705):418-423.

Live Cell Imaging Confocal Microscopy Analysis of HBV Myr-PreS1 Peptide Binding and Uptake in NTCP-GFP Expressing HepG2 Cells. König A, Glebe D. Methods Mol Biol. 2017;1540:27-36.

Detection of hepatitis b virus DNA in the blood of a stem cell donor after granulocyte colony stimulating factor treatment. Punzel M, Medd P, Hunter H, Cunningham R, Pottinger B, Burde B, Widera M, Quade A, Ehninger G, Kozlova A, Schmidt H, Buhrmann K, Schüttler CG, Glebe D, Billen A, Schmidt AH, Mengling T, Verheyen J. Hepatology. 2016 Nov;64(5):1803-1805. doi: 10.1002/hep.28667. Epub 2016 Jul 9.

Characterization of the 3rd International Standard for hepatitis B virus surface antigen (HBsAg). Seiz PL, Mohr C, Wilkinson DE, Ziebuhr J, Schüttler CG, Gerlich WH, Glebe D. J Clin Virol. 2016 Sep;82:166-72. doi: 10.1016/j.jcv.2016.05.009. Epub 2016 Jun 3.

New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen. Kucinskaite-Kodze I, Pleckaityte M, Bremer CM, Seiz PL, Zilnyte M, Bulavaite A, Mickiene G, Zvirblis G, Sasnauskas K, Glebe D, Zvirbliene A. Virus Res. 2016 Jan 4;211:209-21. doi: 10.1016/j.virusres.2015.10.024. Epub 2015 Nov 2.

Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression. Seiz PL, Slanina H, Ziebuhr J, Gerlich WH, Glebe D, Schüttler CG. Int J Med Microbiol. 2015 Oct;305(7):663-72. doi: 10.1016/j.ijmm.2015.08.016. Epub 2015 Aug 21.

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood. Qawasmi M, Samuh M, Glebe D, Gerlich WH, Azzeh M. Hum Vaccin Immunother. 2015;11(7):1717-24. doi: 10.1080/21645515.2015.1041687.

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. Geipel A, Seiz PL, Niekamp H, Neumann-Fraune M, Zhang K, Kaiser R, Protzer U, Gerlich WH, Glebe D; HOPE Consortium..  Antivir Ther. 2015;20(8):779-87. doi: 10.3851/IMP2928. Epub 2015 Jan 5.

Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants. Glebe D, Geipel A. Intervirology. 2014;57(3-4):225-31. doi: 10.1159/000360950. Epub 2014 Jul 15. Review.

Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D. J Hepatol. 2014 Oct;61(4):867-75. doi: 10.1016/j.jhep.2014.05.018. Epub 2014 May 15.

Hepatitis B virus rtI233V mutation and resistance to adefovir. Geipel A, Glebe D, Will H, Gerlich WH. N Engl J Med. 2014 Apr 24;370(17):1667-8. doi: 10.1056/NEJMc1400292. No abstract available.

Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Möller I, Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M. PLoS Pathog. 2014 Jan;10(1):e1003856. doi: 10.1371/journal.ppat.1003856. Epub 2014 Jan 2.

Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Drexler JF, Geipel A, König A, Corman VM, van Riel D, Leijten LM, Bremer CM, Rasche A, Cottontail VM, Maganga GD, Schlegel M, Müller MA, Adam A, Klose SM, Carneiro AJ, Stöcker A, Franke CR, Gloza-Rausch F, Geyer J, Annan A, Adu-Sarkodie Y, Oppong S, Binger T, Vallo P, Tschapka M, Ulrich RG, Gerlich WH, Leroy E, Kuiken T, Glebe D, Drosten C. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16151-6. doi: 10.1073/pnas.1308049110. Epub 2013 Sep 16.

N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus. Bremer CM, Sominskaya I, Skrastina D, Pumpens P, El Wahed AA, Beutling U, Frank R, Fritz HJ, Hunsmann G, Gerlich WH, Glebe D. J Hepatol. 2011 Jul;55(1):29-37. doi: 10.1016/j.jhep.2010.10.019. Epub 2010 Nov 28.

Transient occult hepatitis B virus infection in a blood donor with high viremia. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D. Transfusion. 2009 Aug;49(8):1621-9. doi: 10.1111/j.1537-2995.2009.02188.x

Hepatitis B virus infection is dependent on cholesterol in the viral envelope. Bremer CM, Bung C, Kott N, Hardt M, Glebe D. Cell Microbiol. 2009 Feb;11(2):249-60. doi: 10.1111/j.1462-5822.2008.01250.x. Epub 2008 Nov 5.

Role of glycosaminoglycans for binding and infection of hepatitis B virus. Leistner CM, Gruen-Bernhard S, Glebe D. Cell Microbiol. 2008 Jan;10(1):122-33.